Medeon Biodesign, Inc.

Medeon Biodesign, Inc.

TTPEX:6499
67.30
TWD
-1.60
(-2.32%)
-6.50EPS
6.83BMarket Cap
Mar 04Next Earn

Total Valuation

TWD

As of June 30, 2026, Medeon Biodesign, Inc. carries a market capitalization of 6.83B, placing it among publicly traded companies globally. Its enterprise value stands at 6.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.83B
Enterprise Value6.07B

Important Dates

Medeon Biodesign, Inc.'s next confirmed earnings release is scheduled for March 4, 2027.

Earnings Date3/4/2027

Share Statistics

As of June 30, 2026, Medeon Biodesign, Inc. has 96.94M shares outstanding.

Shares Outstanding96.94M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 15.00, and the price-to-book ratio stands at 5.56.

PS Ratio15.00
PB Ratio5.56
P/TBV Ratio6.31
P/FCF Ratio-13.03
P/OCF Ratio-13.29

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 13.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.07B versus a market cap of 6.83B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales13.60

Financial Position

As of June 30, 2026, Medeon Biodesign, Inc. maintains a current ratio of 6.57, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.94, indicating elevated leverage, while an interest coverage ratio of -117.68 demonstrates limited ability to service its debt obligations.

Current Ratio6.57
Quick Ratio5.84
Debt / Equity11.94
Debt / EBITDA-0.30
Interest Coverage-117.68

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Medeon Biodesign, Inc. posted a negative return on equity (ROE) of -43.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.09, reflecting losses generated across the asset base. The company generates approximately 2.61M in revenue per employee across its workforce of 171.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.05 indicates how many times Medeon Biodesign, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-43.67
Return on Assets (ROA)-35.09
Revenue Per Employee2.61M
Employee Count171.00
Inventory Turnover12.05

Taxes

TWD

Over the twelve months ended June 30, 2026, Medeon Biodesign, Inc. recorded an income tax benefit of -68,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -616.76M and -561.90M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-68,000.00

Stock Price Statistics

TWD

As of the close on November 17, 2026, Medeon Biodesign, Inc.'s stock has declined approximately 32.29% over the past 52 weeks. The 50-day moving average sits at 75.37, while the 200-day moving average is 79.57.

52-Week Price Change-32.29%
50-Day Moving Average75.37
200-Day Moving Average79.57

Income Statement

TWD

Over the twelve months ended June 30, 2026, Medeon Biodesign, Inc. generated 446.15M in revenue and converted that into -561.90M in net income, yielding earnings per share of -6.50. EBITDA reached -512.25M, while operating income came in at -614.51M.

Revenue446.15M
Gross Profit64.28M
Operating Income-614.51M
Pretax Income-616.76M
Net Income-561.90M
EBITDA-512.25M
EBIT-616.05M
Earnings Per Share (EPS)-6.50

Balance Sheet

TWD

As of June 30, 2026, Medeon Biodesign, Inc. holds 959.51M in cash and equivalents against 151.49M in total debt, resulting in a net debt position of -452.47M. Total book value stands at 1.23B, with working capital of 914.43M providing operational flexibility.

Cash & Cash Equivalents959.51M
Total Debt151.49M
Net Debt-452.47M
Equity (Book Value)1.23B
Book Value Per Share12.69
Working Capital914.43M

Cash Flow

TWD

Medeon Biodesign, Inc. produced -503.37M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.24M in capital expenditures, free cash flow totaled -513.61M - equivalent to -5.41 per share.

Operating Cash Flow-503.37M
Capital Expenditures-10.24M
Free Cash Flow-513.61M
FCF Per Share-5.41

Margins

Over the twelve months ended June 30, 2026, Medeon Biodesign, Inc. posted a gross margin of 14.41, reflecting its pricing power and cost economics. The operating margin of -137.73 and net profit margin of -125.94 provide insight into operational efficiency.

Gross Margin14.41
Operating Margin-137.73
Pretax Margin-138.24
Profit Margin-125.94
EBITDA Margin-114.81

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.68: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.57, meaning Medeon Biodesign, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-5.57
FCF Yield-7.68

Stock Splits

Medeon Biodesign, Inc.'s most recent stock split took place on October 22, 2025 with a 507:512 split ratio.

Last Split Date10/22/2025
Split Ratio507:512

Scores

As of June 30, 2026, Medeon Biodesign, Inc. has an Altman Z-Score of 12.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score12.23